Profound Medical Corp
TSX:PRN
Intrinsic Value
Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free a... [ Read More ]
The intrinsic value of one PRN stock under the Base Case scenario is 7.24 CAD. Compared to the current market price of 11.42 CAD, Profound Medical Corp is Overvalued by 37%.
Valuation Backtest
Profound Medical Corp
Run backtest to discover the historical profit from buying and selling PRN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
TULSA's Progress and Expansion in Prostate Treatment
2023-Q4 Earnings Call
In 2023, the groundwork for TULSA as a mainstream prostate cancer treatment was solidified, achieving a significant presence in top US cancer centers. TULSA's installed base is projected to grow to 75 by end-2024. Gaining new CPT codes, TULSA anticipates favorable Medicare reimbursement starting January 2025. Technological advances include FDA's clearance of the Thermal Boost AI module and a pending Contouring Assistant module. The collaboration with Siemens Healthineers aims to deliver a comprehensive diagnostic and interventional MR solution. The company has witnessed 60% growth and expects more, though specific revenue guidance for 2024 wasn't provided.
Balance Sheet Decomposition
Profound Medical Corp
Current Assets | 41.9m |
Cash & Short-Term Investments | 26.2m |
Receivables | 7.3m |
Other Current Assets | 8.4m |
Non-Current Assets | 2m |
PP&E | 1.5m |
Intangibles | 490k |
Current Liabilities | 6.4m |
Accounts Payable | 3.3m |
Other Current Liabilities | 3.1m |
Non-Current Liabilities | 6.4m |
Long-Term Debt | 5.6m |
Other Non-Current Liabilities | 787k |
Earnings Waterfall
Profound Medical Corp
Revenue
|
7.2m
USD
|
Cost of Revenue
|
-2.8m
USD
|
Gross Profit
|
4.4m
USD
|
Operating Expenses
|
-33m
USD
|
Operating Income
|
-28.6m
USD
|
Other Expenses
|
47k
USD
|
Net Income
|
-28.6m
USD
|
Free Cash Flow Analysis
Profound Medical Corp
What is Free Cash Flow?
PRN Profitability Score
Profitability Due Diligence
Profound Medical Corp's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Profound Medical Corp's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
PRN Solvency Score
Solvency Due Diligence
Profound Medical Corp's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Score
Profound Medical Corp's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PRN Price Targets Summary
Profound Medical Corp
According to Wall Street analysts, the average 1-year price target for PRN is 16.38 CAD with a low forecast of 14.26 CAD and a high forecast of 18.9 CAD.
Shareholder Return
PRN Price
Profound Medical Corp
Average Annual Return | 33.67% |
Standard Deviation of Annual Returns | 68.3% |
Max Drawdown | -88% |
Market Capitalization | 279m CAD |
Shares Outstanding | 24 428 900 |
Percentage of Shares Shorted | 0.94% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The company is headquartered in Mississauga, Ontario and currently employs 146 full-time employees. The company went IPO on 2014-09-24. The firm is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum to help preserve the patient’s natural functional abilities. The firm is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Contact
IPO
Employees
Officers
The intrinsic value of one PRN stock under the Base Case scenario is 7.24 CAD.
Compared to the current market price of 11.42 CAD, Profound Medical Corp is Overvalued by 37%.